MORGAN STANLEY ALERT: Bragar Eagel & Squire, P.C. is Investigating Morgan Stanley on Behalf of Morgan Stanley Stockholders and Encourages Investors to Contact the Firm
15 avr. 2024 02h30 HE
|
Bragar Eagel & Squire
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Morgan Stanley (“Morgan...
MS LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Morgan Stanley Investors to Inquire About Securities Class Action Investigation – MS
14 avr. 2024 19h56 HE
|
The Rosen Law Firm PA
NEW YORK, April 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Morgan...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morgan Stanley and Encourages Investors with Losses to Contact the Firm
12 avr. 2024 10h24 HE
|
Schall Law
The Schall Law Firm Announces it is Investigating Claims Against Morgan Stanley and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT: Morgan Stanley Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
11 avr. 2024 15h44 HE
|
Block & Leviton LLP
BOSTON, April 11, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Morgan Stanley (NYSE: MS) for potential securities law violations. Investors who have lost money in their Morgan...
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
05 janv. 2024 09h30 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
19 déc. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
04 déc. 2023 07h09 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Study: Brain Training Improves Cognitive Function In Multiple Sclerosis
06 nov. 2023 07h59 HE
|
Posit Science
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- A study conducted at the University of Nebraska Medical Center showed use of a commercially-available brain training app significantly improved...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
11 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes